German China India

Indonesian Pharmaceutical Market

A Coming Ten Billion Dollar Market: Pharmaceuticals Boom in Indonesia

| Editor: Dominik Stephan

Gallery: 1 image
(Picture: PROCESS India)

Indonesia's pharmaceutical market could nearly double to US $ 9.9 billion by 2020 (from US $ 5 billion). Yet, there are some risks to overcome: ‘Non-efficient and non-transparent IP protection for pharmaceutical products and medical devices leaves major loopholes in Indonesia’s healthcare system,’ a Globaldata analyst says.

Driven by increased government healthcare spending and growing life expectancy, the Indonesian pharmaceutical market value will climb from approximately US $ 5 billion in 2013 to US $ 9.9 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 10.2%, forecasts the research and consulting firm GlobalData. According to the company’s latest report, this growth is due to the introduction of government healthcare reimbursement programs, such as Jamkesmas and the Family Hope Program. Their aim is to provide health insurance to all Indonesians by 2019.

Pharmaceutical Packaging to Grow in Indonesia

Pharmaceutical Packaging

Pharmaceutical Packaging to Grow in Indonesia

20/11/2012 - Growth expected on Indonesia's pharmaceutical market: Manufacturers of packaging solutions like glass specialist Schott present their portfolio at the recent Allpack in Jakarta/Indoneia. The recent trend towards social security and healthcare systems in Asia could offer pharmaceutical service providers and component suppliers new possibilities, company speakers believe... read...

Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “Patented drugs account for the majority of the Indonesian pharmaceutical market. Therapeutic segments, such as infectious and respiratory diseases, are expected to grow significantly in the future, thanks to the increasing incidence of certain communicable diseases.”

Generics Expand Rapidly in Indonesia

“The generic market is also undergoing rapid expansion, boosted by government incentives and the loss of patent protection for several high-selling products. The over-the-counter drug sector reached a 48% share of the pharma market in 2013”, Owide adds. However, the increasing use of generics, coupled with counterfeit medicines, could slow down the Indonesian pharmaceutical industry expansion.

According to Owide, the country’s regulatory system for Intellectual Property (IP) enforcement is problematic on a number of levels, due to inadequate observation and enforcement, and the lack of an effective customs recordal system to discourage infringement of IP rights.

Transparency Still Lacking: Obstacles for the Industry

“Non-efficient and non-transparent IP protection for pharmaceutical products and medical devices leaves major loopholes in Indonesia’s healthcare system. Infringement is common, and penalties include imprisonment for up to seven years and/or a significant fine, but only minor charges are imposed in practice,” Owide says.

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Contact us via: support.vogel.de/ (ID: 42847114 / Business & Economics)